In our study, PG545 significantly reduced the level of TNF-α, and both heparanase inhibitors decreased Casp3 and LC3 levels, effects that are expected to suppress the inflammatory and the pro-fibrotic responses and result in decreased ECM deposition, leading to prevention of liver fibrosis. Here, MAP1LC3A is linked to Hepatic fibrosis.